TMCnet News
CorInnova Awarded "2017 InnoSTARS" Prize for Its Non-Blood-Contacting, Soft Robotic Heart Assist Device as Alternative to LVADs for Treatment of Heart FailureCorInnova Inc., an emerging medical device company developing novel technology for the treatment of Heart Failure, announced today that it was awarded second prize in the "2017 InnoSTARS" life science competition for its EpicHeart™ soft-robotic heart assist device. Hosted by the US China Innovation Alliance (UCIA), China Science and Technology Exchange Center (CSTEC), China Association for International Science and Technology Cooperation (CAISTC), and supported by the Ministry of Science and Technology of People's Republic of China (MOST), the competition provided U.S.-based innovators and companies with a better understanding of the opportunities available to companies interested in doing business in China as well as well as direct interface with qualified Chinese partners and investors. By invitation as a semi-finalist, CorInnova was awarded the trip to China and CorInnova CEO William Altman traveled to Beijing, Tianjin, and Kunming as one of eight semi-finalist life science companies to compete, meet with investors and visit innovation hubs. A total of 300 companies applied to the 2017 InnoSTARS competition across several industry sectors for the opportunity to participate in the business-to-business matchmaking in China. "This InnoSTARS recognition is further validation that our EpicHeart™ technology is innovative and groundbreaking. We believe it will lead to a new paradigm for heart failure treatment," said William Altman, CEO of CorInnova. "Currently, less than 2% of end-stage heart failure patients are treated by transplant or by LVADS. Only about 8% are considered eligible for LVADs due to the invasive surgery required for implantation. "The Chinese and U.S. judges appraised the eight semi-finalist companies not only on the merits of their technology and its ability to fill a large and important unmet medical need, but also on the fit of the technology to the Chinese market," Altman explained. "In this regard, we were very excited to se that the Chinese judges thought EpicHeart was a good fit for, and would find ready adoption in, the large and growing Chinese healthcare market. "We believe that our new approach with EpicHeart™ will potentially quadruple the number of patients who could benefit from a minimally invasive heart assist device," added Altman. "Like the introduction of pacemakers and ICDs to patients with electrical abnormalities affecting heart function, EpicHeart™ has the potential to transform the treatment of heart failure patients worldwide." Click here to see how CorInnova's EpicHeart™ soft robotic, non-blood-contacting heart assist device is delivered minimally invasively to support heart function.
About Heart Failure (HF)
About CorInnova Technology
About CorInnova Inc. CAUTION: The CorInnova technology EpicHeart™ is not approved for human use at this time.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171204005778/en/ |